Xenetic Biosciences, Inc. Appoints James F. Parslow as Principal Accounting Officer, Effective Immediately
April 27, 2017 at 04:15 pm EDT
Share
On April 24, 2017, the Board of Directors of Xenetic Biosciences, Inc. appointed James F. Parslow as the company's principal accounting officer, effective immediately. Mr. Parslow will continue to serve in his current roles as the company's Chief Financial Officer and principal financial officer in addition to his newly appointed role of principal accounting officer. Mr. Parslow has served as the company's Chief Financial Officer since April 3, 2017. Prior to joining the company, he served as Chief Financial Officer, Treasurer and Secretary of World Energy Solutions, Inc. from 2006 until its acquisition by EnerNOC, Inc. in 2015. From 2015 until April 2017, he served as an independent consultant providing interim chief financial officer services to multiple emerging technology companies.
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
XENETIC BIOSCIENCES, INC. 
